Navigation Links
Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
Date:9/5/2008

nd have the potential to form the basis for a new class of diagnostics and therapeutics. MicroRNAs have been shown to have different expression profiles in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory. In Addition, the company expects two additional microRNA diagnostic tests applying its technology will be validated and submitted for regulatory approval by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the potential of microRNAs extracted from blood to serve as effective biomarkers for a wide range of indications, including colon cancer, the role of microRNAs in human physiology and disease, the potential of microRNAs in
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
2. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
3. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
4. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
5. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
6. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... Small print and poor printing on prescription labels ... may lead to errors in taking medication, according ... and CNIB (Canadian National Institute for the Blind)., ... Pharmacists Journal , found that labels on prescription ... professionally recommended guidelines for legibility. , By simply ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... PROVIDENCE, RI The Miriam Hospital received three of ... of Health (NIH) aimed at improving HIV prevention and ... to only a handful of institutions nationwide, are part ... Criminal Justice System NIH,s largest research initiative to ...
... who have hypertension are much more likely to have ... to a new University of Rochester Medical Center (URMC) ... . In fact, when variables such as socio-economic levels ... more likely to have cognitive problems. ...
... HealthDay Reporter , MONDAY, Nov. 8 (HealthDay News) -- New ... smoked may be a different disease than it is in ... cancer tumors in 30 people who never smoked to tumors ... people who had never smoked had twice as many DNA ...
... have found a new pathway for repairing DNA damaged by ... journal Proceedings of the National Academy of Sciences . ... repair oxidative damage," said Peter Beal, professor of chemistry at ... part of its inflammatory response, the body,s immune system produces ...
... November 2010) Results from a European Observational ... today at the Tenth International Congress on Drug ... rate of discontinuation and sustained virologic suppression with ... up to five years. 1 The ...
... OAK BROOK, Ill. Multidetector computed tomography (CT) helps ... type of stroke, potentially speeding the delivery of life-saving ... the January issue of Radiology . ... first-line imaging tool for identifying the cause of acute ...
Cached Medicine News:Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 2Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 3Health News:Children with high blood pressure more likely to have learning disabilities 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 3Health News:New DNA repair pathway 2Health News:Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients 2Health News:Using CT, radiologists can pinpoint cause of some strokes 2